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Summary
Background Obesity disproportionately affects African Ameri-
cans (AA) (especially women), and is linked to depressed 25-
hydroxyvitamin D (25-OH D) and elevated parathyroid hormone
(PTH). The relationship of 25-OH D and PTH with body composi-
tion and size in AA is not well known.
Objective To determine the relationship of 25-OH D and PTH
levels with body composition and anthropometric measures.
Design A cross-sectional study was conducted in 98 healthy,
overweight, adult AA enrolled in an NIH/NIEHS-sponsored weight
loss/salt-sensitivity trial.
Measurements Multivariable linear regression analyses were
used to explore the relationship of 25-OH D and PTH with
body composition, determined by dual-energy X-ray absorptio-
metry, and anthropometric measures. Body composition and
size were contrasted across vitamin D/PTH groups using general
linear models: (i) normal (25-OH D >50 nmol/l, PTH £65 pg/
ml), (ii) low 25-OH D and normal PTH and (iii) low 25-OH
D and high PTH.
Results Age, gender and season-adjusted regression analyses
showed that PTH was directly correlated with total (P = 0Æ02),
truncal (P = 0Æ03) and extremity (P = 0Æ03) fat mass, while 25-OH
D was inversely related to truncal fat mass (P = 0Æ02). Total fat
mass in groups 1–3, respectively, was 30Æ0, 34Æ0 and 37Æ4 kg
(P = 0Æ008); truncal fat mass was 13Æ4, 15Æ9 and 17Æ6 kg
(P = 0Æ006) and extremity fat mass was 15Æ8, 16Æ9 and 19Æ7 kg
(P = 0Æ02). Lean mass did not differ across the three groups.
Conclusions Our findings show that lower 25-OH D and raised
PTH are both correlated, though in opposite directions, with fat
mass, fat distribution and anthropometric measures in adult AA.
(Received 7 March 2009; returned for revision 20 April 2009; finally
revised 19 June 2009; accepted 8 July 2009)
Introduction
Obesity is a risk factor for a multiplicity of cardiovascular diseases.1
The prevalence of overweight and obesity is significantly more
common in adult African Americans (AA) than whites.2 This is
particularly true amongst women who are less physically active and
have elevated hypertension, and diabetes mellitus, two obesity-
related conditions, relative to white women than is observed in AA
men relative to white men.2,3 Several epidemiological studies have
linked vitamin D deficiency to obesity.4–15 Data from the Third
National Health and Nutrition Examination Survey (1988–1994)
showed that serum 25-hydroxycholecalciferol (25-OH D) was
lower in non-Hispanic blacks in comparison with that in both
Mexican Americans and non-Hispanic whites.4 Furthermore,
vitamin D deficiency is strikingly more prevalent in AA women
than in white women.5 Epidemiological studies document that
both hypovitaminosis D and secondary hyperparathyroidism are
highly prevalent in AA compared with that in whites, particularly
in obese AA.6,7
To date, most studies have correlated circulating 25-OH D and/
or parathyroid hormone (PTH) levels with crude body size
measures, such as body mass index (BMI), and markers of body
composition, such as percent body fat. Several cross-sectional
studies have reported a strong inverse association between 25-OH
D and obesity (BMI, waist circumference, waist to hip ratio, total
body fat percentage and total body fat mass), as well as a direct
association between PTH and obesity.6,8–15 However, other studies
have shown a weaker inverse correlation between 25-OH D and
percent body fat in AA compared with that in whites of the same
age,16 and no correlation between serum 25-OH D and BMI17,18 or
between PTH and body weight.19 However, little is known in AA or
any other racial/ethnic group about the relationship of body
composition and lean and fat mass distribution in relation to the
levels of vitamin D and PTH.
Thus, we undertook these analyses to determine the relationship
between 25-OH D and PTH with body composition, lean and fat
mass distribution and body size in healthy AA. The healthy cohort
of AA in this work provides a unique opportunity to study these
relationships before the development of hypertension, diabetes and
other obesity-related morbidities.
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Methods
A cross-sectional design was used in an all AA cohort recruited in
Detroit, Michigan, for a salt-sensitivity/weight loss study. Data
were collected between February 2004 and March 2008. Personal
identifiers were removed prior to importing the data into a research
database for analysis. This study was reviewed and approved by the
Wayne State University, Institutional Review Board. Signed
informed consent was obtained from all participants prior to their
participation.
Study population
The study population was comprised of 98 healthy, normotensive
(blood pressure <140/90 mmHg), overweight (BMI = 25–
39Æ9 kg/m2) AA men and women aged 35 years and older who
were enrolled in an NIH/NIEHS-sponsored clinical trial – ‘Obes-
ity, Nitric Oxide and Salt Sensitivity’. Participants were excluded
for the following reasons: medical illness, those consuming >3
alcoholic drinks per day, eating >6 restaurant meals per week,
taking oral steroids or nitrates, nonsteroidal antiinflammatory
drugs >4 days/week, using supplemental vitamins/herbs, working
night shift, actively dieting or losing weight and/or planning to
move >50 miles or travel extensively from the area during
the next 12 months. They were also excluded for refusing to
give informed consent, refusing venipuncture and/or having a
positive pregnancy test (given to premenopausal women who
have not had a hysterectomy and have not been surgically
sterilized).
Study measures
Venous blood sampling was performed in all participants to mea-
sure circulating 25-OH D and PTH in serum. To minimize varia-
tions, both 25-OH D and PTH were processed in batches.
25-OH vitamin D
25-Hydroxyvitamin D was measured using liquid chromato-
graphy-tandem spectrometry at Mayo Medical Laboratories, MN.
Functional sensitivity (FS) of the assay was <10 nmol/l and the
mean interassay coefficient of variation (CV) was 3Æ8%.
Intact PTH
Intact PTH was measured using immunochemiluminometric
assay and electrochemiluminescence method at Mayo Medical
Laboratories, MN. FS of the assays was <5 pg/ml and <6 pg/ml,
respectively, and mean interassay CV was 8% and 6–7%, respec-
tively. Validation using least square linear regression analysis by
Mayo Laboratories resulted in a good linear fit (R2 = 0Æ99)
between the assays and produced a linear equation [electro-
chemiluminescent = (0Æ7721 · immunometric) + 2Æ9337]. To be
consistent, this equation was used to convert PTH values obtained
from immunometric assay into values from electrochemilumines-
cent assay. Converted PTH values (N = 48) and PTH values from
electrochemiluminescent assay (N = 50) were used for statistical
analysis.
Dietary data
Block 98 Food Frequency Questionnaire (FFQ) was completed by
each participant to capture usual eating patterns over the last
12 months.20 Daily vitamin D, caloric, calcium and magnesium
intakes were estimated from FFQ records that were analysed with
the Nutrition Data System, research version of the software (Uni-
versity of Minnesota, Nutrition Coordinating Center). Calcium
and magnesium intakes were from dietary and supplemental
sources, whereas vitamin D intake was solely from diet.
Physical activity
Physical activity was assessed using the MESA Typical Week Physical
Activity Survey (MESA-TWPAS). The survey is designed to capture
typical activity patterns in one’s daily life by identifying the time and
frequency spent in various physical activities during a typical week
in the past month. The survey consisted of 28 questions that covered
household chores, lawn/yard/garden/farm work, care of children/
adults, transportation, walking (not at work), dancing/sport activi-
ties, conditioning activities, leisure activities, occupational activities
and volunteer activities. Minutes spent per activity were converted
into hours. The total hours spent per week for the nine physical
activity categories were multiplied by the metabolic equivalent
(MET) level21 to obtain an estimated score for the self-reported
physical activity in units of MET-h/week. Light (mostly comprised
of indoor activities), moderate and vigorous (mostly comprised of
outdoor activities) physical activity scores were also calculated. We
excluded three participants who did not complete the survey and 15
who reported an average physical activity per day of more than 24 h.
Body mass index
Height was measured using a stadiometer to the nearest 0Æ001 m.
Body weight was measured using a standard balance beam scale to
the nearest 0Æ1 kg. BMI was calculated as body weight divided by
the square of their height (kg/m2).
Waist and hip circumference
Waist circumference was measured to the nearest 0Æ1 cm by apply-
ing the measuring tape horizontally midway between the lowest rib
and the iliac crest after a normal expiration. Hip circumference was
measured at the point yielding the maximum circumference over
the greater trochanter.
Body composition
Dual-energy X-ray absorptiometry (DEXA) measurements were
performed in all participants using a total body scanner (QDR 4500
Acclaim Series Elite, Hologic Inc., Bedford, MA, USA). DEXA is a
noninvasive method of assessing bone mineral, fat and bone-free
lean mass, requiring the participant to lie supine for 5–10 min.22
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Repeatability errors (CV) obtained with DEXA are: fat, in grams
(and percent total mass), CV = 2Æ6%; lean, in grams, CV = 0Æ9%.
Total, truncal and extremity fat mass and corresponding lean mass
were evaluated. Extremity fat mass and lean mass were comprised
of both upper and lower limbs. Truncal fat mass and lean mass were
comprised of thoracic, abdominal and pelvic regions.
Statistical analysis
Continuous data were summarized as mean values, medians,
standard deviations and 95% confidence intervals (CI), while
categorical variables were summarized as frequencies and counts.
The distributions of all continuous variables were examined for
skewness/normality using Shapiro-Wilk statistic. Continuous data
that deviate significantly from normality were transformed to the
natural logarithm to approximate a normal distribution prior to
analysis. The independent sample t-test and the Wilcoxon
signed-rank test were utilized to compare mean values of contin-
uous variables. Pearson correlation coefficient (r) and Spearman’s
rank correlation coefficient (rs) were used to display the univari-
ate strength and direction of the relationship between selected
study variables. Wilcoxon test and Spearman correlation were
used for the physical activity variables because these variables
were skewed. As the data for the vigorous physical activity score
had many zero values, the distribution showed over-dispersion.
Thus, an over-dispersed generalized linear model (GLM) using
generalized estimation equation was used to compare the mean
value of vigorous physical activity score between men and
women.
Primary analyses utilized multivariable regression models
adjusted for age, gender and season to characterize the relationship
of 25-OH D and PTH with fat mass and body size. Three dummy
variables were used for seasonal adjustment where the months of
the year were stratified into four groups: January–March (used as
the reference group), April–June, July–September and October–
December. To allow for considerations of the joint effects of 25-OH
D and PTH, a secondary analytical approach was performed utiliz-
ing age, gender and season-adjusted GLM to contrast body compo-
sition (fat mass and lean mass) and anthropometric measures
(BMI, weight and hip circumference) across three mutually
exclusive vitamin D/PTH groups: (i) normal [25-OH D = 51–
249 nmol/l (1 nmol/l = 0Æ4 ng/ml), PTH £ 65 pg/ml (1 pg/
ml = 1 ng/l)]; (ii) LN or low 25-OH D and normal PTH and
(iii) secondary hyperparathyroidism (SHPT) or low 25-OH D and
high PTH. Dietary intakes (caloric, vitamin D, calcium and magne-
sium) were also contrasted across the three groups using age and
gender-adjusted GLM. If a difference is detected among the vitamin
D/PTH groups, Bonferroni’s correction, a multiple comparisons
procedure, was utilized to determine which vitamin D/PTH groups
were significantly different. Adjusted GLM was also applied to
determine statistical significance of between-group differences
comparing study variables between the normal and the combined
abnormal (LN + SHPT) groups. Statistical analyses were
performed using sas statistical software (SAS, version 9.1, SAS
Institute Inc., Cary, NC, USA). Statistical significance was set at
P < 0Æ05.
Imputation of missing data
Only 77 participants had complete dietary data. As deletion of
incomplete cases may result in severe bias as well as loss of power,
multiple imputation (MI) was utilized to fill in the missing values.
MI is a Markov-chain Monte Carlo technique23 in which the
missing values are replaced by more than one simulated versions
using R statistical software (R, version 2.7.0, Vienna, Austria). The
rate of our missing information was not high (21%); therefore,
three imputations were used to analyse multivariable regression
models. Results from the three imputed data sets were very similar.
We reported results from both the original data set (n = 77) and
from one imputed data set (n = 98). Imputation was also applied
for the physical activity data.
Results
Study subjects characteristics
The majority of participants were women. There were no gender
differences in average 25-OH D and average PTH levels (Table 1).
The average 25-OH D level was in the range considered to represent
vitamin D deficiency (25-OH D £50 nmol/l).24 However, the aver-
age PTH level was within the normal range. Average BMI was in the
obese range (BMI ‡30 kg/m2). On average, women had greater fat
body mass, BMI and hip circumference than men. The average lean
body mass was greater in men than women. The average total physi-
cal activity did not differ between men and women. Men had higher
mean caloric intake but lower mean calcium and mean magnesium
intakes than women. However, average calcium, magnesium and
vitamin D intakes were all below daily recommended intakes.
About 5% of the participants had optimal vitamin D level of
‡75 nmol/l.24,25 The highest serum 25-OH D level was 95 nmol/l, a
level below the vitamin D toxicity level of >250 nmol/l.25 Nearly
one-fifth of the participants had vitamin D insufficiency (25-OH
D = 51–74 nmol/l).24 The remaining three quarters of the study
cohort had vitamin D deficiency (25-OH D £50 nmol/l)24 in which
a third had vitamin D levels £25 nmol/l.
Correlation of 25-hydroxyvitamin D with physical activity
and dietary vitamin D
25-hydroxyvitamin D was positively correlated with vigorous phys-
ical activity score (original: rs = 0Æ25, P = 0Æ02; imputed: rs = 0Æ22,
P = 0Æ03) and with dietary vitamin D intake that was borderline
significant (original: r = 0Æ09, P = 0Æ42; imputed: r = 0Æ19,
P = 0Æ05).
Relationships of 25-hydroxyvitamin D and parathyroid
hormone levels with fat mass and anthropometric
measures
Parathyroid hormone and 25-OH D were regressed on fat mass
and anthropometric measures using age, gender and season-
adjusted multivariable regression models (Table 2). There were no
interactions between either PTH or 25-OH D with gender in these
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analyses. Table 2 shows the 25-OH D and PTH regression coeffi-
cients from three different linear regression models using total,
truncal and extremity fat mass, BMI, hip and waist circumferences
as dependent variables. Linear regression models 1 and 2 display
the association of 25-OH D and PTH with dependent variables,
respectively, and model 3 displays the association of both 25-OH
D and PTH with dependent variables.
Total body fat mass. PTH was directly related to total fat mass
(P = 0Æ02, model 2). However, the strength of the association
Table 1. Characteristics of all study subjects and gender stratification.
Characteristic
All Female Male
P-valueN = 98 N = 82 N = 16
Age (years) 49Æ0 (7Æ0) 49Æ5 (7Æ2) 46Æ6 (5Æ6) 0Æ13
25-OH D (nmol/l) 40Æ4 (18Æ9) 40Æ6 (19Æ1) 39Æ3 (18Æ8) 0Æ80
PTH (pg/ml) 42Æ7 (26Æ0) 43Æ6 (27Æ2) 38Æ3 (19Æ1) 0Æ45
Fat distribution (kg) N = 98 N = 82 N = 16
Total fat mass 33Æ5 (8Æ6) 35Æ3 (7Æ6) 24Æ2 (7Æ4) <0Æ0001
Truncal fat mass 15Æ5 (4Æ3) 16Æ1 (4Æ1) 12Æ5 (4Æ2) 0Æ002
Extremity fat mass 17Æ0 (4Æ9) 18Æ2 (4Æ1) 10Æ5 (3Æ4) <0Æ0001
Lean distribution (kg) N = 98 N = 82 N = 16
Total lean mass 52Æ5 (9Æ5) 47Æ0 (5Æ6) 66Æ0 (7Æ3) <0Æ0001
Truncal lean mass 24Æ0 (4Æ3) 22Æ1 (2Æ8) 30Æ1 (3Æ6) <0Æ0001
Extremity lean mass 24Æ3 (5Æ0) 21Æ4 (2Æ8) 31Æ5 (3Æ8) <0Æ0001
Anthropometric Measures N = 98 N = 82 N = 16
BMI (kg/m2) 31Æ8 (3Æ6) 32Æ1 (3Æ6) 30Æ1 (3Æ3) 0Æ04
Hip circumference (cm) 115Æ4 (9Æ0) 116Æ2 (9Æ0) 110Æ9 (7Æ9) 0Æ03
Waist circumference (cm) 98Æ6 (10Æ5) 98Æ0 (10Æ6) 101Æ3 (9Æ4) 0Æ25
Waist:Hip ratio 0Æ86 (0Æ08) 0Æ84 (0Æ07) 0Æ91 (0Æ06) 0Æ0007
Physical activity score – original N = 80 N = 67 N = 13
cTotal (MET-h/week) 215Æ3 (109Æ6) 208Æ8 (112Æ2) 249Æ1 (91Æ9) 0Æ13
cLight (MET-h/week) 83Æ9 (52Æ2) 87Æ6 (54Æ4) 64Æ5 (34Æ6) 0Æ15
cModerate (MET-h/week) 57Æ5 (63Æ6) 53Æ8 (30Æ5) 76Æ6 (55Æ9) 0Æ05
Vigorous (MET-h/week)† 12Æ9 (29Æ7) 9Æ8 (22Æ5) 28Æ9 (52Æ1) 0Æ02
Physical activity score – imputed N = 98 N = 82 N = 16
Total (MET-h/week)* 220Æ3 (121Æ5) 219Æ1 (125Æ3) 226Æ2 (103Æ1) 0Æ54
Light (MET-h/week)* 86Æ6 (58Æ5) 91Æ8 (61Æ0) 59Æ9 (33Æ7) 0Æ05
Moderate (MET-h/week)* 67Æ4 (67Æ1) 64Æ7 (69Æ3) 81Æ5 (54Æ6) 0Æ09
Vigorous (MET-h/week)† 17Æ3 (31Æ0) 14Æ7 (25Æ7) 30Æ8 (49Æ3) 0Æ03
Dietary intake – original N = 77 N = 70 N = 7
Calorie (kcal/day) 2159 (1346) 1946 (863) 4280 (2938) 0Æ08
Calcium (mg/1000 kcal/day) 479 (265) 498 (270) 291 (66) <0Æ0001
Magnesium (mg/1000 kcal/day) 168 (54) 172 (55) 124 (17) <0Æ0001
Vitamin D (IU/day) 257 (200) 248 (192) 350 (269) 0Æ19
Dietary intake – imputed N = 98 N = 82 N = 16
Calorie (kcal/day) 2404 (1536) 1962 (890) 4670 (2106) 0Æ0001
Calcium (mg/1000 kcal/day) 420 (287) 460 (290) 217 (159) <0Æ0001
Magnesium (mg/1000 kcal/day) 162 (154) 176 (164) 90 (49) 0Æ0002
Vitamin D (IU/day) 277 (192) 264 (191) 340 (195) 0Æ14
Values are expressed as mean, with corresponding standard deviations (SD) in parentheses. Comparison between male and female groups using the indepen-
dent sample t-test or otherwise indicated – *Wilcoxon signed-rank test or †over-dispersed generalized linear model using generalized estimation equation.
25-OH D, 25-hydroxyvitamin D; PTH, parathyroid hormone; BMI, body mass index; MET, metabolic equivalent; IU, international unit.
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between PTH and total fat mass became borderline significant after
adjustment for 25-OH D levels (P = 0Æ06, model 3). 25-OH D
showed a trend towards a negative correlation that did not quite
attain statistical significance before (model 1) and after adjustment
for PTH levels (model 3).
Truncal fat mass. Truncal fat mass demonstrated an inverse rela-
tionship with 25-OH D (P = 0Æ02, model 1) and a direct relation-
ship with PTH (P = 0Æ03, model 2). The inverse association
between 25-OH D and truncal fat mass became borderline signifi-
cant (P = 0Æ09, model 3) after adjustment for PTH levels. However,
PTH lost its significant direct relationship with truncal fat mass
after adjustment for 25-OH D levels.
Extremity fat mass. Parathyroid hormone was directly related to
extremity fat mass (P = 0Æ03, model 2). The direct association
between PTH and extremity fat mass remained statistically signifi-
cant after adjustment for 25-OH D levels (P = 0Æ04, model 3).
25-OH D was unrelated to extremity fat mass even after adjustment
for PTH levels.
Body mass index. 25-Hydroxyvitamin D was inversely associated
with BMI (P = 0Æ01, model 1), although PTH was not. The rela-
tionship between 25-OH D and BMI remained significant even
after adjustment for PTH levels (P = 0Æ04, model 3).
Hip circumference. The inverse association of 25-OH D (P = 0Æ07,
model 1) and the direct association of PTH (P = 0Æ06, model 2) with
hip circumference were both borderline significant. The strength of
the associations of 25-OH D and PTH with hip circumference was
not significantly influenced when PTH or 25-OH D, respectively,
was considered simultaneously in the regression models.
Waist circumference. 25-Hydroxyvitamin D was inversely related
to waist circumference both before (P = 0Æ01, model 1) and after
(P = 0Æ01, model 3) adjustment for PTH levels. PTH, on the other
hand, was unrelated to waist circumference.
Body composition, body size and dietary intakes across
the vitamin D/PTH categories
25-hydroxyvitamin D and PTH. 25-Hydroxyvitamin D trended
lower when progressing from the normal to the most abnormal
vitamin D/PTH groups (P < 0Æ0001). The normal group had sig-
nificantly greater 25-OH D level (67Æ7 (95% CI: 63Æ2–72Æ2) nmol/l)
that was more than two times the 25-OH D levels of the LN (32Æ4
(29Æ6–35Æ2) nmol/l) and SHPT (26Æ4 (19Æ6–33Æ3) nmol/l) groups.
25-OH D levels for the LN and SHPT groups were within the range
of vitamin D deficiency of £50 nmol/l,24 with the lowest levels in
the latter group. PTH trended higher towards the most abnormal
vitamin D/PTH group (P < 0Æ0001). PTH level in SHPT group
(97Æ6 (87Æ1–108Æ2) pg/ml) was approximately three times greater
than PTH levels in both the normal (32Æ0 (25Æ1–39Æ0) pg/ml) and
LN (37Æ2 (32Æ9–41Æ5) pg/ml) groups. Both the normal and LN
groups had comparable normal PTH levels.
Body composition. Total body fat mass (P = 0Æ008), truncal fat mass
(P = 0Æ006) and extremity fat mass (P = 0Æ02) were incrementally
higher from the normal group to the most abnormal vitamin
D/PTH group (Fig. 1). The differences (all statistically significant)
in total body fat mass, truncal fat mass and extremity fat mass
between the normal and SHPT groups were 27%, 31% and 25%,
respectively. However, the difference between the normal and LN
group was statistically significant only for truncal fat mass. Further-
more, total fat mass (P = 0Æ01) and truncal fat mass (P = 0Æ003)
were greater in the combined abnormal groups relative to the
normal group. Extremity fat mass was also greater in the combined
abnormal groups compared with that in the normal group, which
was of borderline significance (P = 0Æ08). Total body, truncal and
extremity lean mass did not differ across the vitamin D/PTH groups.
Table 2. Regression coefficients for the regression of fat distribution and











1 25-OH D )65Æ2 (0Æ10)
2 PTH 69Æ2 (0Æ02) +1Æ8 kg
3 25-OH D )39Æ3 (0Æ34)
PTH 59Æ5 (0Æ06) +1Æ5 kg
Truncal fat
mass (g)
1 25-OH D )49Æ0 (0Æ02) )0Æ9 kg
2 PTH 34Æ2 (0Æ03) +0Æ9 kg




1 25-OH D )15Æ8 (0Æ46)
2 PTH 34Æ4 (0Æ03) +0Æ9 kg
3 25-OH D )10Æ0 (0Æ96)
PTH 34Æ1 (0Æ04) +0Æ9 kg
Body mass index
(kg/m2)
1 25-OH D )0Æ04 (0Æ01) )0Æ76 kg/m2
2 PTH 0Æ02 (0Æ17)




1 25-OH D )0Æ09 (0Æ07) )1Æ70 cm
2 PTH 0Æ07 (0Æ06) +1Æ82 cm




1 25-OH D )0Æ14 (0Æ01) )2Æ65 cm
2 PTH 0Æ03 (0Æ47)
3 25-OH D )0Æ14 (0Æ01) )2Æ65 cm
PTH )0Æ004 (0Æ92)
Multivariable linear regression models adjusted for age, gender and seasons.
Values are expressed as regression coefficients and P-values are in parenthe-
ses. Values for one-standard deviation (1-SD) higher indicate measurable
amounts of dependent variables that correspond to 1-SD higher PTH or
25-OH D levels. 1-SD higher is calculated by multiplying regression
coefficient by 1-SD value of either PTH or 25-OH D. 1-SD 25-OH
D = 18Æ9 nmol/l; 1-SD PTH = 26Æ0 pg/ml. For example, a 1-SD higher
PTH level corresponded to: 1Æ8 kg higher total fat mass (P = 0Æ02, model
2), 0Æ9 kg higher truncal fat mass (P = 0Æ03, model 2) and 0Æ9 kg higher
extremity fat mass (P = 0Æ03, model 2) and 1Æ82 cm greater hip
circumference (P = 0Æ06, model 2). A 1-SD lower 25-OH D level
corresponded to: 0Æ9 kg greater truncal fat mass (P = 0Æ02, model 1),
0Æ76 kg/m2 higher BMI (P = 0Æ02, model 1), 1Æ70 cm greater hip
circumference (P = 0Æ07, model 1) and 2Æ65 cm greater waist circumference
(P = 0Æ01, model 1).
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Anthropometric measures. Body mass index (P = 0Æ002), waist
(P = 0Æ02) and hip (P = 0Æ03) circumferences were monotonically
higher across the three vitamin D/PTH groups (Table 3). The
differences in BMI, waist and hip circumferences between
the normal and SHPT groups were 12%, 7% and 7%, respectively.
The difference between the normal and SHPT groups for BMI and
hip circumference and the difference between the normal and
LN groups for BMI and waist circumference were statistically
significant. In addition, BMI (P = 0Æ0007), waist circumference
(P = 0Æ007) and hip circumference (P = 0Æ02) were greater in the
combined abnormal groups vs. the normal group. There was no
significant difference in weight and height across the vitamin
D/PTH groups.
Dietary intake. The incrementally lower daily caloric, vitamin D,
calcium and magnesium intakes across the vitamin D/PTH groups
were not statistically significant (Table 3). Magnesium intake was
borderline higher in the normal group compared with that in the
combined abnormal groups (P = 0Æ06).
Discussion
Our cross-sectional study in overweight adult AA demonstrated
that depressed 25-OH D and raised PTH levels were both linked to
body composition, fat distribution and anthropometric measures.
Surprisingly, lean body mass, which was expected to increase with
increasing physical load of higher fat mass, did not differ across the
vitamin D/PTH groups. Currently published data predicting
hormonal correlates for body fat and body size are not well-
documented. We reported new observations in an overweight AA
cohort linking 25-OH D closely to truncal fat mass, BMI and waist
circumference, and linking PTH closely to total fat mass and
extremity fat mass.
Most studies have correlated obesity with vitamin D and PTH
separately.6,8–10,12–15,26 A recent work by Rejnmark and colleagues
further showed the relationship of PTH with the two locations of
fat mass – trunk and extremity, in vitamin D insufficient postmeno-











































Fig. 1 Fat distribution across the vitamin D/PTH Groups. Least square
means with corresponding standard errors of fat mass across the vitamin
D/PTH groups using general linear models adjusted for age, gender and
season. Total, truncal and extremity fat mass were incrementally higher
from the normal to the most abnormal vitamin D/PTH groups to a signifi-
cant degree. Bonferroni’s correction detected significant differences
between (*) the normal and SHPT groups and between (+) the normal and
LN groups. (a) P = 0Æ01 vs. LN + SHPT; (b) P = 0Æ003 vs. LN + SHPT; (c)
P = 0Æ08 vs. LN + SHPT. Normal, normal 25-OH D and normal PTH
(n = 24); LN, low 25-OH D and normal PTH (n = 63); SHPT, secondary
hyperparathyroidism group or low 25-OH D and high PTH (n = 11).
Normal 25-OH D >50 nmol/l; Normal PTH £65 pg/ml.
Table 3. Anthropometric measures and dietary intakes across the vitamin D/PTH groups
Dependent Variable Normal LN SHPT
P-valueCharacteristics† (N = 98) N = 24 N = 63 N = 11
Age (years) 50Æ3 (47Æ5–53Æ2) 48Æ5 (46Æ7–50Æ2) 49Æ3 (45Æ1–53Æ5) 0Æ52
Gender (% female) 20 (83) 52 (83) 10 (91) 0Æ79
Anthropometric measures‡ (N = 98)
Body mass index (kg/m2) 29Æ7 (28Æ3–31Æ0)ab 32Æ3 (31Æ5–33Æ2)a 33Æ3 (31Æ3–35Æ4)b 0Æ002
Waist circumference (cm) 93Æ7 (89Æ6–97Æ8)a 100Æ2 (97Æ6–102Æ8)a 100Æ0 (93Æ7–106Æ2) 0Æ02
Hip circumference (cm) 111Æ7 (108Æ2–115Æ3)b 116Æ0 (113Æ8–118Æ2) 119Æ5 (114Æ1–124Æ9)b 0Æ03
Waist:Hip ratio 0Æ84 (0Æ81–0Æ87) 0Æ86 (0Æ85–0Æ88) 0Æ84 (0Æ80–0Æ89) 0Æ31
Dietary Intake – imputed* (N = 98)
Vitamin D (IU/day) 317 (241–394) 278 (231–325) 177 (65–290) 0Æ12
Calorie (kcal/day) 2448 (1972–2924) 2421 (2128–2714) 2208 (1506–2910) 0Æ83
Magnesium (mg/1000 kcal/day) 207 (151–264) 150 (116–185) 128 (44–211) 0Æ17
Calcium (mg/1000 kcal/day) 451 (339–564) 420 (351–489) 354 (189–520) 0Æ63
Values are expressed as least square mean values with corresponding 95% confidence intervals in parentheses, unless otherwise indicated. *General linear
models adjusted for age and gender only. †Unadjusted general linear models. ‡General linear models adjusted for age, gender and season. Bonferroni’s
correction detecting a difference that was statistically significant between athe normal and LN groups and between bthe normal and SHPT groups. Normal,
normal 25-hydroxyvitamin D (25-OH D) and normal parathyroid hormone (PTH); LN, low 25-OH D and normal PTH; SHPT, secondary hyperparathyroid-
ism group or low 25-OH D and high PTH. Normal 25-OH D >50 nmol/l; Normal PTH £65 pg/ml.
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combined effect of 25-OH D and PTH on body composition and
body size. Our findings show that total, truncal and extremity fat
mass were incrementally higher when moving from the normal to
the most abnormal vitamin D/PTH group.
Our study supports a positive association of serum 25-OH D
levels with both dietary vitamin D intake and vigorous physical
activity,17,18,27 which is mostly comprised of outdoor activities.
However, vitamin D deficiency is highly prevalent in our study
cohort. Approximately three quarters of the participants were vita-
min D deficient (25-OH D £50 nmol/l).24 Thus, we chose a lower
25-OH D threshold of normalcy of 50 nmol/l in combination with
a threshold PTH value of 65 pg/ml7,25 for the secondary analyses.
Previous studies on elderly and other population with limited
sunlight exposure and susceptibility to low vitamin D levels have
utilized a 25-OH D cut-off value of 50 nmol/l.11,28 A recent epide-
miological study in AA utilized a much lower 25-OH D threshold
of 37Æ5 nmol/l.6 We performed sensitivity analyses contrasting fat
mass and anthropometric measures utilizing age, gender and
season-adjusted GLM across the vitamin D/PTH groups using a
lower 25-OH D threshold value of 37Æ5 nmol/l in combination
with a PTH threshold value of 65 pg/ml and also using a lower
PTH threshold value of 45 pg/ml in combination with a 25-OH D
threshold value of 50 nmol/l; the findings were in agreement with
the trends observed using a combination of a 25-OH D threshold
value of 50 nmol/l and a PTH threshold value of 65 pg/ml.
It has long been accepted that both depressed 25-OH D and reac-
tive rises in PTH were consequences of obesity. Both the level and
conversion of 7-dehydrocholesterol to vitamin D3 in the skin are
normal in obese persons. However, the increase in circulating vita-
min D3 after UV light exposure is lower in obese than that in non-
obese subjects.14 Thus, the reduced serum vitamin D3 level is
probably attributable to sequestration of fat-soluble vitamin D3 in
adipocytes.10 However, it is also plausible that depressed 25-OH D
and elevated PTH levels might play a role in the development of
obesity, as there are known physiological mechanisms through
which depressed 25-OH D and/or PTH elevations promote the
accumulation of adipose tissue.
Elevated PTH augments renal 25-hydroxyvitamin D3-1alpha-
hydroxylase (1a-hydroxylase) activity, producing an increase in
circulating 1,25-(OH)2 D.
29 Production of 1,25-(OH)2 D from
kidneys is the only pathway that is, however, tightly regulated by
negative calcitriol feedback on 1a-hydroxylase activity. The enzyme
1a-hydroxylase, which is expressed predominantly in the kidney, is
also expressed in a number of extra-renal sites, such as skin, gastro-
intestinal tract, vasculature, immune cells, bones and adipocytes.30,31
Activation of extra-renal 1a-hydroxylase is shown to be independent
of PTH and the extra-renal 1,25-(OH)2 D production is dependent
on the availability of its substrate, 25-OH D.32,33 Currently, the
involvement of extra-renal 1a-hydroxylase in fat accumulation is
not known. Nevertheless, several studies suggest that circulating
1,25-(OH)2 D is elevated in AA compared with that in whites.
34–38
Raised PTH levels, as a consequence of low 25-OH D and/or
decreased calcium intake, stimulate a rise in intracellular calcium
level in adipocytes via activation of phospholipase C-b.39 Likewise,
increased circulating levels of 1,25-(OH)2 D, as a consequence of
PTH-induced renal 1a-hydroxylation of 25-OH D, raise intracellu-
lar calcium levels in adipocytes via a nongenomic action by activat-
ing the putative 1,25 D3-membrane-associated rapid response to
steroid, a membrane vitamin D receptor (VDR).39–44 The increased
intracellular calcium is an important second messenger that trig-
gers various pathways that promote the accumulation of adipose
tissue, including activation of lipogenesis by augmenting fatty acid
synthase activity,42,43 suppression of catecholamine-induced lipo-
lysis by activating phosphodiesterase-3B42,45 and augmentation of
reactive oxygen species (ROS), promoting adipocyte proliferation
by activating oxidative enzymes [such as nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase and myeloperoxidase]
and protein kinase C that stabilizes NADPH oxidase complex to
generate more ROS.46 In addition, increased ROS levels further
augment intracellular calcium levels. Furthermore, 1,25-(OH)2 D
also binds to nuclear VDR (nVDR) down-regulating uncoupling
protein 2 expression and activity; this genomic effect inhibits adi-
pocyte apoptosis and activates adipocyte proliferation.47,48 1,25-
(OH)2 D also suppresses the activity of caspases 1 and 3, leading to
suppression of adipocyte apoptosis by enhancing Bcl2/Bax.47,48 A
recent study by Sun and Zemel (2008) showed that 1,25-(OH)2 D
increases glucocorticoid production by binding to nVDR.
Increased glucocorticoid increases nVDR, thereby creating a posi-
tive feedback that promotes further synthesis of glucocorticoid.49
Moreover, 1,25-(OH)2 D augments adipocyte lipid accumulation
through increased fatty acid uptake via activation of lipoprotein
lipases.50 Therefore, it is physiologically plausible, though unpro-
ven, that low levels of circulating 25-OH D and reactive rise in
PTH levels contribute to accumulation of adipose tissue.
Limitations
The current study is cross-sectional and therefore the cause and
effect between low 25-OH D, raised PTH and obesity cannot be
established. We enrolled a relatively modest sample size and there-
fore may have inadequate power to detect definitively important
associations. The majority, though not all, of our participants were
women. Thus, we did not have enough men to report any meaning-
ful gender-specific analyses. Furthermore, we did not determine
the menopausal state of women, which may influence circulating
25-OH D levels. Moreover, we did not measure 1,25-(OH)2 D, the
biologically active form of vitamin D.
Conclusion
Our cross-sectional study found an association of low 25-hydroxy-
vitamin D and raised parathyroid hormone with greater adiposity,
body mass index, and waist and hip circumferences in overweight
adult African Americans. The logical next step is to design human
experiments to determine if raising vitamin D levels leads to
reduction in fat mass, body fat distribution and/or waist and hip
circumferences.
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